PEDIATRIC PSORIASIS | CELGENE PPSO-003 | PHASE III

Status: RECRUITING

Drug: Apremilast – CC-10004

Timeline:  19 visits over 66 weeks

Detailed Description

This is a phase 3, multi-centre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of apremilast (CC-10004) in pediatric subjects from 6 to 17 years of age with moderate to severe plaque psoriasis.

Inclusion

• Informed consent
• Male or Female
• Age 6 to 17 years old
• Able to swallow study medication tablet
• Diagnosis of chronic plaque psoriasis for at least 6 months prior to screening

Exclusions

• Female subjects who are pregnant or lactating
• Significant medical history
• Previous treatment with aprelimast

If you’re interested in participating, please SEND US AN EMAIL AND/OR CONTACT US and our research team will be in touch.